Phase 1b Multi-Indication Study of the Antibody Drug Conjugate Anetumab Ravtansine in Patients with Mesothelin-Expressing Advanced or Recurrent Malignancies

被引：0
|
作者：
Adjei, A. [1 ]
Walter, A. [2 ]
Cupit, L. [3 ]
Siegel, J. [3 ]
Holynskyj, A. [3 ]
Childs, B. [3 ]
Elbi, C. [3 ]
机构：
[1] Mayo Clin, Rochester, NY USA
[2] Bayer AG, Berlin, Germany
[3] Bayer Healthcare Pharmaceut, Whippany, NJ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-013
引用
收藏
页码：S1976 / S1976
页数：1
相关论文
共 50 条
  • [21] A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.
    Krishnan, Amrita Y.
    Shah, Nina
    Spira, Alexander I.
    Kaufman, Jonathan L.
    Niesvizky, Ruben
    Shah, Nirav Niranjan
    Burke, John M.
    Popplewell, Leslie
    Martin, Thomas G.
    Cheung, Julee
    Matheny, Shannon L.
    Leonard, John Paul
    Molina, Arturo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met-targeting antibody-drug conjugate, in select advanced solid tumor indications.
    Perets, Ruth
    Sharma, Manish
    Strickler, John H.
    Golan, Talia
    Hollebecque, Antoine
    Henner, William
    Vasilopoulos, Athanasios
    Thiele, Gladys Morrison
    Burns, Michael Charles
    Harding, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] A PHASE 1B STUDY OF BRIVANIB IN COMBINATION WITH 5FU/LVAND FOLFIRI IN PATIENTS WITH ADVANCED OR METASTATIC GASTRO-INTESTINAL MALIGNANCIES
    Hollebecque, A.
    El-Khoueiry, A.
    Jonker, D. J.
    Sawyer, M. B.
    Wong, L.
    Becerra, C. R.
    Soria, J. C.
    Chemidlin, J. M.
    Kollia, G.
    Nuyten, D. S. A.
    ANNALS OF ONCOLOGY, 2013, 24 : 34 - 34
  • [24] A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C
    Kim, Richard
    Leal, Alexis D.
    Parikh, Aparna
    Ryan, David P.
    Wang, Shining
    Bahamon, Brittany
    Gupta, Neeraj
    Moss, Aaron
    Pye, Joanna
    Miao, Harry
    Inguilizian, Haig
    Cleary, James M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (04) : 291 - 300
  • [25] Correction to: A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C
    Richard Kim
    Alexis D. Leal
    Aparna Parikh
    David P. Ryan
    Shining Wang
    Brittany Bahamon
    Neeraj Gupta
    Aaron Moss
    Joanna Pye
    Harry Miao
    Haig Inguilizian
    James M. Cleary
    Cancer Chemotherapy and Pharmacology, 2023, 91 (4) : 301 - 301
  • [26] A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results
    Sawas, Ahmed
    Savage, Kerry J.
    Perez, Raymond
    Advani, Ranjana H.
    Butturini, Anna
    Lackey, Jacqueline
    Trave, Fabio
    Anand, Banmeet
    Huang, Yao
    Reyno, Leonard
    O'Connor, Owen A.
    BLOOD, 2015, 126 (23)
  • [27] Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies
    Daruka Mahadevan
    Gregory Ryan Sutton
    Rafael Arteta-Bulos
    Chris J. Bowden
    Paul J. E. Miller
    Rachel Elizabeth Swart
    Mark S. Walker
    Paul Haluska
    Pamela N. Munster
    John Marshall
    Omid Hamid
    Razelle Kurzrock
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 467 - 473
  • [28] Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies
    Mahadevan, Daruka
    Sutton, Gregory Ryan
    Arteta-Bulos, Rafael
    Bowden, Chris J.
    Miller, Paul J. E.
    Swart, Rachel Elizabeth
    Walker, Mark S.
    Haluska, Paul
    Munster, Pamela N.
    Marshall, John
    Hamid, Omid
    Kurzrock, Razelle
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 467 - 473
  • [29] A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer
    Cho, Byoung Chul
    Johnson, Melissa
    Bar, Jair
    Schaefer, Eric
    Yoh, Kiyotaka
    Zer, Alona
    Moskovitz, Mor
    Lee, Se-Hoon
    Moreno, Victor
    de Miguel, Maria
    Okuma, Yusuke
    Kim, Joo-Hang
    Lee, Chun-Hui
    Peguero, Julio
    Ansell, Peter
    Biesdorf, Carla
    Saab, Rabih
    Freise, Kevin J.
    Ramies, David
    Jeng, Edwin E.
    Camidge, D. Ross
    LUNG CANCER, 2025, 202
  • [30] A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors
    Tolcher, A. W.
    Calvo, E.
    Maitland, M. L.
    Gibson, B.
    Xuan, D.
    Joh, T.
    Jackson-Fischer, A.
    Damelin, M.
    Barton, J.
    Xin, X.
    Sachdev, J. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S724 - S724
12345